Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a biopharmaceutical company developing treatments for serious diseases using novel sGC stimulators, targeting both the central nervous system (CNS) and the periphery. Its pipeline includes Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator in Phase 2 clinical trials for cardiovascular diseases, and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. The company has a license agreement with Akebia covering the development, manufacture, medical affairs, and commercialization of Praliciguat and related products. Cyclerion Therapeutics was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.